Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, Villalobos P, Neggers JE, Mendiratta S, Wei S, Landesman Y, Senapedis W, Baloglu E, Chow CB, Frink RE, Gao B, Roth M, Minna JD, Daelemans D, Wistuba II, Posner BA, Scaglioni PP, White MA. Kim J, et al. Among authors: landesman y. Nature. 2016 Oct 6;538(7623):114-117. doi: 10.1038/nature19771. Epub 2016 Sep 28. Nature. 2016. PMID: 27680702 Free PMC article.
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.
Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. Tai YT, et al. Among authors: landesman y. Leukemia. 2014 Jan;28(1):155-65. doi: 10.1038/leu.2013.115. Epub 2013 Apr 16. Leukemia. 2014. PMID: 23588715 Free PMC article.
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. Salas Fragomeni RA, et al. Among authors: landesman y. Mol Cancer Ther. 2013 Jul;12(7):1171-9. doi: 10.1158/1535-7163.MCT-12-1171. Epub 2013 Apr 24. Mol Cancer Ther. 2013. PMID: 23615632
Clinical translation of nuclear export inhibitors in cancer.
Senapedis WT, Baloglu E, Landesman Y. Senapedis WT, et al. Among authors: landesman y. Semin Cancer Biol. 2014 Aug;27:74-86. doi: 10.1016/j.semcancer.2014.04.005. Epub 2014 Apr 19. Semin Cancer Biol. 2014. PMID: 24755012 Review.
Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB. Yang J, et al. Among authors: landesman y. PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014. PLoS One. 2014. PMID: 25057921 Free PMC article.
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y, Kauffman MG, Shacham S, Pennati M, Zaffaroni N. De Cesare M, et al. Among authors: landesman y. Oncotarget. 2015 May 30;6(15):13119-32. doi: 10.18632/oncotarget.3761. Oncotarget. 2015. PMID: 25948791 Free PMC article.
121 results